SillaJen, Inc.

A215600

KR7215600008

Biotechnology & Medical Research

End-of-day quote Korea S.E. Other stock markets 23:00:00 27/06/2024 BST			5-day change	1st Jan Change
3,650 ^KRW	+1.25%		+2.82%	-39.47%

04-22	OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market	CI
03-27	SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC	CI

SillaJen, Inc. announced that it has received KRW 40 billion in funding

August 30, 2021

On August 31, 2021, SillaJen, Inc closed the transaction.

Latest news about SillaJen, Inc.

OSR Holdings and SillaJen Enter into A Memorandum of Understanding to Collaborate the Development of Innovative Therapeutics and Enter the U.S. Market	04-22	CI
SillaJen, Inc. Submits CSR to the US FDA for REN026 Study in Patients with RCC	03-27	CI
SillaJen to Raise 129.4 Billion Won via Shares Issuance	03-25	MT
SillaJen, Inc.(KOSDAQ:A215600) added to S&P Global BMI Index	18/09/23	CI
Switzerland's Basilea Pharmaceutica Secures $4 Million Milestone Payment for Oncology Asset	19/12/22	MT
SillaJen Resumes Trading on Kosdaq	13/10/22	MT
SillaJen Bags Licensing Right to Basilea Pharmaceutica's Oncology Drug	21/09/22	MT
Kosdaq Delists Biotechnology Company SillaJen	19/01/22	MT
An unknown buyer agreed to acquire a 5.1% stake in NeoImmuneTech, Inc. from SillaJen, Inc. for KRW 10.1 billion.	24/11/21	CI
SillaJen, Inc. announced that it has received KRW 40 billion in funding	30/08/21	CI
SillaJen, Inc. announced that it has received KRW 60 billion in funding from M2N Co.,Ltd	14/07/21	CI
SillaJen, Inc. announced that it expects to receive KRW 40 billion in funding	13/07/21	CI
SillaJen, Inc. announced that it expects to receive KRW 60 billion in funding from M2N Co.,Ltd	30/05/21	CI
M2N Co.,Ltd signed LOI to acquire SillaJen, Inc..	20/04/21	CI
SillaJen, Inc.(KOSDAQ:A215600) dropped from S&P Global BMI Index	21/09/20	CI
SillaJen, Inc.(KOSDAQ:A215600) dropped from FTSE All-World Index	21/09/20	CI
SillaJen, Inc. announced that it has received KRW 20 billion in funding	23/04/20	CI
SillaJen, Inc. announced that it expects to receive KRW 20 billion in funding	22/04/20	CI
Sillajen Announces Conclusions from Interim Futility Analysis of Phase 3 PHOCUS Trial in HCC	02/08/19	CI
SillaJen Announces First Patient Enrolled in Part 2 of Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Libtayo® (cemiplimab-rwlc)	06/06/19	CI
SillaJen, Inc. announced that it has received KRW 110 billion in funding	20/03/19	CI
SillaJen, Inc. announced that it expects to receive KRW 110 billion in funding	18/03/19	CI
SillaJen, Inc. Announces First Patient Enrolled in Renal Cell Carcinoma Trial with Pexa-Vec in Combination with Regeneron's Cemiplimab	20/06/18	CI
SillaJen, Inc.(KOSDAQ:A215600) added to FTSE All-World Index	19/03/18	CI
SillaJen, Inc.(KOSDAQ:A215600) added to FTSE All-World Index	19/03/18	CI

SillaJen Inc is a Korea-based company primarily engaged in the research and development of oncolytic virus immunotherapeutics. The Companyâs major product is Pexa-Vec, which is in a global Phase 3 clinical trial that is used for the treatment of liver cancer. Additionally, it also offers oncolytic virus immunotherapeutics, including SJ-102, SJ-103, SJ-815, JX-929, JX-930, JX-963, JX-970 and others.970 and others.

Sector

Biotechnology & Medical Research

Calendar

12/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
SILLAJEN, INC.	-39.47%	272M
VERTEX PHARMACEUTICALS INCORPORATED	+15.20%	121B
REGENERON PHARMACEUTICALS, INC.	+19.67%	113B
ARGENX SE	+18.95%	26.02B
BIONTECH SE	-23.86%	19.39B
GENMAB A/S	-19.03%	15.91B
BEIGENE, LTD.	-20.90%	15.09B
WUXI APPTEC CO., LTD.	-46.14%	15.06B
SAREPTA THERAPEUTICS, INC.	+63.85%	14.93B
NEUROCRINE BIOSCIENCES, INC.	+4.49%	13.85B